PeopleBio KRX:304840KOSDAQ
피플바이오 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days2
Articles tracked2since Sep 11
In Q2 2026, PeopleBio reported revenue of ₩1.7bn, up 127.9% year on year, and an operating loss of ₩749m. PeopleBio (피플바이오) appeared in 0 Korean news articles and 2 DART filings over the past seven days.
Filing signals Split / consolidation 4 quarters of losses Share pledge Screener
PeopleBio quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩1.7bn | +127.9% | −₩749m margin −44.9% | −₩1.9bn |
| Q1 2026 | ₩643m | -17.5% | −₩1.5bn margin −230.5% | – |
| Q4 2025 derived | ₩154m | -76.7% | −₩1.7bn | – |
| Q3 2025 | ₩1.2bn | +23.2% | −₩2.1bn margin −174.6% | – |
| Q2 2025 | ₩733m | -46.4% | −₩2.0bn margin −269.6% | – |
| Q1 2025 | ₩780m | +4.7% | −₩2.6bn | – |
| Q4 2024 derived | ₩658m | -49.3% | −₩1.9bn margin −282.3% | – |
| Q3 2024 | ₩962m | -8.3% | −₩3.3bn | – |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
PeopleBio top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest PeopleBio news Korean headlines
-
강성민 피플바이오 대표 “美서 LDT·진단키트 사업 본격화… 내년부터 매출 가시화”
1 more on this story · 1 outlets
- 강성민 피플바이오 대표 “美서 LDT·진단키트 사업 본격화… 내년부터 매출 가시화”이데일리 · Sep 19 08:07